Elucidating the genetic control of cerebral cortical (pallial) development is essential for understanding function, evolution, and disorders of the brain. Transcription factors (TFs) that embryonically regulate pallial regionalization are expressed in gradients, raising the question of how discrete domains are generated. We provide evidence that small enhancer elements active in protodomains integrate broad transcriptional information. CreER T2 and GFP expression from 14 different enhancer elements in stable transgenic mice allowed us to define a comprehensive regional fate map of the pallium. We explored transcriptional mechanisms that control the activity of the enhancers using informatics, in vivo occupancy by TFs that regulate cortical patterning (CoupTFI, Pax6, and Pbx1), and analysis of enhancer activity in Pax6 mutants. Overall, the results provide insights into how broadly expressed patterning TFs regulate the activity of small enhancer elements that drive gene expression in pallial protodomains that fate map to distinct cortical regions.
SUMMARY
Elucidating the genetic control of cerebral cortical (pallial) development is essential for understanding function, evolution, and disorders of the brain. Transcription factors (TFs) that embryonically regulate pallial regionalization are expressed in gradients, raising the question of how discrete domains are generated. We provide evidence that small enhancer elements active in protodomains integrate broad transcriptional information. CreER T2 and GFP expression from 14 different enhancer elements in stable transgenic mice allowed us to define a comprehensive regional fate map of the pallium. We explored transcriptional mechanisms that control the activity of the enhancers using informatics, in vivo occupancy by TFs that regulate cortical patterning (CoupTFI, Pax6, and Pbx1), and analysis of enhancer activity in Pax6 mutants. Overall, the results provide insights into how broadly expressed patterning TFs regulate the activity of small enhancer elements that drive gene expression in pallial protodomains that fate map to distinct cortical regions.
INTRODUCTION
At the core of cortical development lie transcriptional programs that orchestrate a sequence of processes beginning with specification of the cortical anlage and its regional subdivisions, or the protomap (Rakic, 2009 ; O' Leary et al., 2013) . Ongoing work has identified a set of transcription factors (TFs) that control the size and areal identities of pallial subdivisions. These include CoupTFI, Dmrta2 (Dmrt5) , Emx2, Lef1, Lhx2, Pax6, and Sp8 (Bishop et al., 2000; Galceran et al., 2000; Yun et al., 2001; Mallamaci and Stoykova, 2006; Armentano et al., 2007; Sahara et al., 2007; Faedo et al., 2008; Mangale et al., 2008; Chou et al., 2009; Konno et al., 2012; Borello et al., 2013; Saulnier et al., 2013) . Each of these TFs is expressed in distinct gradients in progenitor cells of the pallial ventricular zone (VZ). For instance, Pax6 is expressed in rostrocaudal and ventrodorsal gradients; Pax6 loss of function in mice results in a respecification of cortical regions along both its rostrocaudal and ventrodorsal axes (Bishop et al., 2000; Yun et al., 2001) . Despite the subdivision of the pallium into discrete structural/molecular units (e.g., the medial, dorsal, lateral, and ventral pallium [MP, DP, LP, and VP]; Puelles et al., 2000) , to date the TFs that are known to control regional fate are expressed in gradients across these subdivisions, raising the intriguing question of how these gradients are interpreted in an integrative fashion to generate sharply delineated pallial subdivisions and later adult cortical regions.
One mechanism that could solve this conundrum would be that enhancer elements integrate TF expression to generate gene activation in distinct pallial subdivisions, much in the way that regional fate is generated in the cellular blastoderm of Drosophila embryos (Lagha et al., 2012) . While this general paradigm had previously been supported through anecdotal reports of individual pallial enhancers identified in gene-centric studies (Kammandel et al., 1999; Theil et al., 2002; van den Bout et al., 2002; Ahituv et al., 2007; Colasante et al., 2008) , a recent more comprehensive screen for forebrain enhancers that includes spatial activity data for $145 human enhancers that are active in the embryonic day (E) 11.5 mouse telencephalon enables a rigorous and systematic search for enhancers involved in prepatterning of the pallium (Visel et al., 2013) . Here we present evidence that enhancers integrate information from TF gradients in the embryonic day E11.5 mouse pallium to generate distinct expression domains. Using a panel of 14 human enhancers carefully selected based on their in vivo activity patterns, we generated a set of stable mouse transgenic lines that express CreER T2 and GFP in distinct domains within the developing pallium. Leveraging this unique set of reporter mice, we derived fate maps that elucidate the embryonic origin of pallial subdivisions. Furthermore, we used a combination of bioinformatics, chromatin immunoprecipitation sequencing (ChIP-seq), and in vivo studies to elucidate the regulation of these enhancers by major pallial transcription factors including COUPTFI, PAX6, and PBX1. Overall, we propose that the enhancers defined through this study identify protodomains of the pallial neuroepithelium, which may be fundamental units of cortical development and evolution.
RESULTS

Pallial Protodomains Identified by Enhancer Activity Using Transient Transgenic Assay
To define enhancers potentially marking neuroepithelial subdivisions in the E11.5 pallium, we mined a previously described large collection of enhancers active in the developing telencephalon, assayed using transient transgenic mouse LacZ expression (Visel et al., 2013) . We identified more than 40 enhancers that showed regional pallial expression, many of which showed intrapallial boundaries ( Figures 1A-1C and Figure S1 available online). For instance, in the MP, several enhancer lines showed nested patterns of expression, varying between a small dorsocaudal domain (643), a domain in the ventral caudomedial telencephalon (653), a larger domain that includes the entire caudomedial telencephalon (192) , and the entire dorsomedial and caudomedial region including the primordial septum (348) (Figure 1C) . Regional patterns of activity were also observed for enhancers expressed in the DP, LP, and VP (Figures 1A and 1B) . We mapped these expression limits onto a model schema of the E11.5 pallial neuroepithelium, from which we hypothesize the existence of a set of sharply delimited pallial progenitor domains or protodomains (A-I) ( Figure 1D ; Table S1 ).
Enhancer Activity of Pallial Enhancer CreER
T2 -IRES-
GFP Alleles
To test the idea that these human enhancers are active in protodomains that generate distinct pallial subdivisions, we produced stable transgenic mouse lines to characterize the properties of 14 enhancers that reproducibly exhibited boundaries in the E11.5 pallium ( Figures 1A-1C and Figure S1 ; asterisks label the enhancers used to make stable lines). We generated stable transgenic mouse lines that express CreER T2 -IRES-GFP and downstream of each one of the 14 selected ''pallial'' enhancers and a minimal Hsp68 promoter. We generated two to three founders for 10/14 of the lines; their expression domains were reproducible (Table S2) . We further analyzed the properties of one founder for each enhancer.
To characterize the activity of each enhancer, we defined the GFP expression at E11.5 and compared the enhancer activity in the stable and transient transgenic assays. The stable lines showed enhancer activity patterns that closely resembled the transient transgenic assay (Table S2) . We annotated the E11.5 expression domains on a flattened topologic representation of the embryonic pallium (right hemisphere), where stippled gray color indicates GFP expression (Figures 2I and 2I 0 and Figures  S2A-S2N ). For instance, for enhancer 643, we observed progenitor GFP expression in the MP at E11.5 (Figures 2A-2H ). On the other hand, enhancer 1,050 showed progenitor GFP expression in the DP and MP at E11.5 but was absent in the ventrolateral pallium (VLP) (Figures 2A 0 -2H 0 ). Next, we examined prenatal GFP expression at E12.5, E14.5, and E17.5 for all of the lines ( Figures S2A-S2N and Table S2 ). In most cases, enhancer activity was strongest at E11.5 and was largely unchanged at E12.5 (Table S2) . However, activity patterns of some of the enhancers were more dynamic. For instance, 636 was selectively active in the VLP at E10.5, but by E11.5, its activity was greatly reduced ( Figure S2E ). Activity of 12/14 enhancers decreased and/or became restricted to a smaller domain by E14.5 and E17.5 (Table S2 ). For instance, 218, 281, 653, and 1,318 activity was no longer detected in the pallium by E14.5. Three of the enhancers with MP expression (348, 643, and 1,006) were no longer active in the hippocampus but maintained activity in the hippocampal fissure, choroid plexus, and fimbrial area. The activity of 636, 840, and 1,172 became restricted to small populations of cells in the pallium at E17.5 (Figures S2E , S2I, and S2M). Enhancer 660, which was active in the caudoventral MP at E11.5, became active in the SVZ and superficial cortical layers of the DP at E17.5 ( Figure S2H ).
Fate Mapping Using Pallial Enhancer CreER
T2 -IRES-GFP
Alleles
To determine the identity of the cells whose progenitors have E11.5 enhancer activity, we performed fate map analyses by introducing the Ai14 (tdTomato) Cre reporter allele (Madisen et al., 2010) into the enhancer CreER T2 -IRES-GFP lines. We administered tamoxifen at E10.5 to induce CreER T2 translocation to the nucleus, where it activated tdTomato expression and then performed neuroanatomical analyses at later stages. Because of the $24-36 hr window of tamoxifen action (Hayashi and McMahon, 2002) , we assessed enhancer activity at both E11.5 and E12.5 to better interpret the results of E10.5 tamoxifen treatment ( Figure S2 and Table S2 ). Since prenatal tamoxifen treatment frequently led to fetal death around the time of delivery, we obtained fate-mapping data at E17.5 for all enhancer lines. However, we also obtained postnatal fate maps (P30) for a subset of the enhancers (192, 348, 636, 643, 653, and 660; Figure S2 and Table S3 ). We chose these enhancers because of their activity in the hippocampus; the hippocampus matures later than the neocortex; thus, P30 data helped analysis of the hippocampal fate map. We annotated the fate map domains on a flattened topological representation of the maturing/mature pallium (Figures 2S and 2S 0 and Figure S2 ). Here we indicated anatomical locations containing tdTomato + cells using a graded rating scale of 1-4: 1 (red) high density to 4 (green) almost no tdTomato + cells ( Figures 2S and 2S 0 ). For instance, 643, which showed E11.5 activity restricted to the MP, fate mapped to the rostrodorsal CA fields, dentate gyrus of the rostrodorsal hippocampus, the fimbrial area, and choroid plexus ( Figures 2J-2R and 5B-5B 000 ). On the other hand, 1,050, which showed E11.5 activity restricted to DP and MP, was fate mapped to the neocortex and hippocampus and only weakly labeled the LP (insular cortex) and did not label the VP (piriform cortex) (Figures 2J 0 -2R 0 ). Similar analyses were performed for all the enhancer lines; the data and analyses are compiled in Figures S2A-S2N . From these experiments, we have deciphered the embryonic origin of pallial subdivisions (see schema of pallial progenitor subdivisions in Figure 1E and Tables S3 and S4); we have organized these data into Figures 3, 4 , and 5, which focus on the frontal cortex, ventrolateral cortex, and hippocampal structures, respectively.
Enhancers Active in Primordia of Distinct Frontal Cortex Subdivisions
The analysis of E11.5 expression and CreER T2 fate-mapping experiments from 11 enhancer transgenic lines demonstrated which progenitor domains generated cells that populated different subdivisions of the prefrontal cortex (PFC) ( Figure 3 and Figure S2 ; Tables  S3 and S4 ). Fate mapping of enhancer lines (192, 348, 1, 056) with E11.5 activity in the rostral-most E11.5 MP resulted in labeled cells in the medial PFC (MPFC). Enhancer 192 activity generated tissue probably representing the indusium griseum and taenia tecta (Figures 3A-3A 000 and Figure S2A ); 1,056 generated the ventromedial PFC (including the medial orbital cortex) (Figures 3B-3B 000 and Figure S2L ); 348 generated most regions of the MPFC ( Figures 3C-3C 000 and Figure S2D ). Fate mapping of enhancer lines (218, 840, and 1,050) with E11.5 activity in the rostral-most DP ( Figure 3 , Figure S2 , and Table S4 ) resulted in labeling of the dorsal PFC (DPFC). For instance, 1,050 only generated cells in the DPFC ( Figures 3D-3D 000 and Figure S2K ). Fate mapping of enhancer lines (281, 636, and 1,172) that showed expression in the rostral-most E11.5 VLP (Figure 3 and Figure S2 ) resulted in cells of the lateral PFC (LPFC). This included the anterior insular cortex and the lateral orbital PFC (Figure 3 and Figure S2 ). Finally, fate mapping of 1,318 and 1,006 activities, which were similar in the rostral telencephalic pole at E11.5, resulted in cells that populate the entire PFC (Figure 3I and Figures S2J and S2N ). These data are summarized in Figure 3I , Figure S2 , and Tables S3 and S4 .
Enhancers Active in Primordia of Distinct VP and LP Subdivisions
The analysis of E11.5 expression and CreER T2 fate-mapping experiments from eight enhancer transgenic lines identified progenitor domains generating the VP and LP, which contain cortical domains superficial to pallial nuclei (Puelles, 2014) (Figures 4K and Figure S2 ). To systematize the E17.5 fate-mapping analyses, we compared the td-Tomato expression with the expression of two proteins that have boundaries in the VP and LP domains: NURR1 (NR4A2) and CTIP2 (BCL11B) (Figure 4 ). NURR1 was expressed dorsally in the claustrum, a nucleus lying deep to the insular cortex (LP) and more ventrally in the dorsal endopiriform nucleus, which is deep to the piriform cortex (VP).
We defined boundary 1 as the dorsal limit of the claustrum and boundary 3 as the ventral limit of the endopiriform nuclei (Figures 4B-4B 000 , 4E-4E 000 , and 4H-4H 000 ). CTIP2 was expressed in the superficial corticoid strata of these two pallial regions; we defined boundary 2 as the limit between the insular cortex and the piriform cortex and boundary 4 as the ventral limit of the VP with the subpallium (Figures 4C-4C 000 , 4F-4F 000 , and 4I-4I 000 ). Fate maps from the ventrolateral enhancers (Figures 4 and S2) showed different tdTomato + cell distributions in the ventrolateral cortices. Rostrally, enhancers 1,050, 1,006, 218, 281, and 636 showed progressively more ventral boundaries. Cells marked by 1,050 activity were restricted to the DP (ending before the LP), 1,006 ended roughly at the DP/LP boundary, 218 ended roughly at the LP/VP boundary, and 281 and 636 extended to the pallial-subpallial boundary ( Figures 4A-4F 000 and Figures  S2C, S2E , and S2J). Enhancer 636 was most active in the VLP, with little activity in the DP ( Figures 4A-4C 000 and Figure S2E ). Figure 4J shows enhancer fate map annotation along the dorsoventral axis in separate rostral, middle, and caudal regions. Some enhancers had clear rostrocaudal differences in the dorsoventral position of their respective fate maps (281, 636, 1,172, and 1,318) . For instance, 1,172 labeled a domain that rostrally was largely ventrally restricted, whereas caudally it extended into the DP and MP ( Figure S2M ). Note that enhancer 1,172 maps to a genomic region $100 kb away from CoupTFI, which shows a very similar expression pattern ( Figure S2M , Table S2 ; Armentano et al., 2007; Faedo et al., 2008) .
Enhancers Active in Primordia of MP Subdivisions: Hippocampal Complex and Adjacent Structures E11.5 expression and fate-mapping experiments from six enhancer transgenic lines demonstrate the progenitor domains that generate different MP derivatives; these enhancers were active either in the rostrodorsal or caudoventral hippocampal fields (Figures 5, 6F , and 6G and Figure S2 ). Note that the dorsoventral adult hippocampal topography corresponds topologically to the embryonic rostrocaudal axis, the ventral tip next to the amygdala being caudalmost. The hippocampal region is topologically dorsal; the choroid plexus (Ch) Figure S2A ). Enhancer 643 was active in the progenitors of the Ch, F, CR cells, dentate gyrus (DG), and CA fields (strongest in CA1) (Figures 5B-5B 000 and Figure S2F ). Its activity was restricted to the rostrodorsal MP. Likewise, 218 was active in progenitors of the rostrodorsal MP but was weak in caudoventral MP progenitors ( Figure S2B ). Enhancer 348 was active in the entire MP but with stronger activity in its rostrodorsal components ( Figures 5A-5A 000 and 5D-5D 00 and Figure S2D ). By contrast with these rostrodorsal MP enhancers, we identified two MP enhancers that were almost exclusively restricted to the caudoventral MP: 653 and 660. These were active in progenitors that produced cells in the caudoventral DG and CA fields ( Figures 5E-5E 000 and Figures S2G and S2H ).
Enhancer 643 Marks the Formation of the Hippocampal Field
Based on the nested activity of enhancers 192, 643, and 348 within the hippocampal primordia (GFP expression and fate maps), we studied its ontogenesis in detail by examining enhancer MP activity at E11.5 ( Figure 6 ). We compared the expression of GFP and Lmx1a RNA, a marker of the F and Ch (Chizhikov et al., 2010) . Histochemical analysis at E11.5 showed that GFP expression from enhancers 192 and 643 and Lmx1a Figures 6C-6C 00 ), whereas enhancer 643 GFP expression spread into the adjacent pallial neuroepithelium (between arrowhead and arrow; Figures  6D-6D 00 ). Recall that enhancer 192 fate mapping labeled very little of the hippocampus, whereas enhancer 643 fate mapping labeled the DG and the CA fields of the rostrodorsal hippocampus ( Figures 5C-5C 000 , arrows, and 6C). Thus, the hippocampal field is first detectable between E11.5 and E12.5, concomitant with the expansion of enhancer 643 activity ( Figure 6E ).
Computational Identification of Transcriptional Drivers of Region-Specific Enhancer Activity
To explore the molecular mechanisms controlling enhancer activity in subregions of the pallium, we compared the sequences of enhancers with activity largely restricted specific pallial domains. We were most successful when we compared MP enhancer sequences (N = 9; 192, 348, 480, 611, 622, 643, 653, 660, 1,006) to the sequence of enhancers active in DP, LP, and VP (N = 15; 22, 200, 218, 488, 595, 619, 632, 636, 671, 876, 957, 978, 987, 1, 025, 1, 050) . We searched for nucleotide motifs that distinguished these groups using two models. Model 1 was trained to distinguish sequence motifs between 9 MP enhancers, 15 non-MP enhancers, and 480 random genomic sequences. Model 2 was trained to distinguish sequence motifs between 9 MP enhancers, 15 non-MP enhancers, a set of background sequences consisting of 480 random genomic sequences, and 765 sequences from the VISTA Enhancer Browser that were negative for enhancer activity (see Supplemental Experimental Procedures). This approach generated motifs that were enriched in MP enhancers compared to non-MP enhancers. The top 20 de novo motifs for each set of enhancers (MP and non-MP) were mapped to the Transfac and JASPAR database to identify TFs that have similar binding sites ( Figure S3 ; see Tables S5 and S6) .
Using the list of TF binding motifs preferentially identified in MP enhancers or in non-MP enhancers, we scrutinized the E11.5 expression of the top 40 TFs using the Allen Brain Atlas (http:// developingmouse.brain-map.org/). Five TFs (Lhx5, AR, Nr4a2 [nuclear receptor family], Lmx1a, and Foxj1) were only expressed in the Ch/F domain, and five TFs showed expression in the DP, but not in the MP, and especially in Ch/F, expression was either low or not detectable (Figures S3 and S4 and Tables S5 and S6) . Thus, the method successfully selected for TFs that were either expressed within or excluded from Ch/F. Of note, the Ch is perhaps the most distinct region of the pallium, because its derivative, the choroid plexus, is a nonneural structure.
Transcriptional Mechanisms Regulating Enhancer
Function: In Vivo Binding by PAX6, COUPTFI, and PBX1 Next, we directly screened the enhancers for binding sites for TFs known to regulate pallial pattering. We found binding sites for PAX6, COUPTFI (NR2F1), and PBX1 in pallial enhancers (Genomatix); each of these TFs regulates patterning of the pallial primordium (Bishop et al., 2000; Yun et al., 2001; Mallamaci and Stoykova, 2006; Armentano et al., 2007; Faedo et al., 2008 ; O.G. and J.L.R.R., unpublished data). We then tested whether these enhancers were bound in vivo by these TFs using chromatin immunoprecipitation and DNA sequencing (ChIP-seq). We performed ChIP-seq with antibodies to PAX6 (n = 3), COUPTFI (n = 1), and PBX1 (n = 1) on dissected E12.5 mouse pallium; information about the quality of the sequence mapping and peak calling are reported in Table S7 . We surveyed the genome for binding to the 44 enhancers assayed in Figure 1 and Figure S1 . The results are organized according to the regional activity of the enhancers, MP (n = 11), DP+MP (n = 8), DP (n = 2); LVP+DP; LVP (n = 12), and MP+DP+LVP (n = 6) (Table S8 ). Then, we annotated ChIP-seq binding to each enhancer by PAX6, COUPTFI, and PBX1.
PAX6 bound to all of the enhancers that were globally expressed (MP+DP+LVP) in the pallium (6/6). As the enhancers became more restricted in their regional activity, PAX6 binding frequency reduced, particularly if LVP activity was absent. PAX6 and COUPTFI (NR2F1) bound to few MP enhancers, and PBX1 bound none ( Figure 7A and Table S8 ). We show an example of PAX6 peaks over enhancer 840 and 636 ( Figure 7C ), and PAX6, COUPTFI, and PBX1 binding over the other enhancers are shown in Figure S5 .
We then focused on Pax6 regulation of some of the enhancers that had in vivo binding sites. We used transient transfection luciferase assays to study whether Pax6 cotransfection modulated activity of 636, 643, 840, and 1,172 (n = 4). In each case, we observed >5-fold activation of luciferase expression (Figure 7B ). Of note, PAX6 activation declined in enhancers with MP activity (840, 643) or that were expressed in a caudorostral gradient (1,172; note: Pax6 is expressed in a rostocaudal gradient).
Finally, we tested Pax6 in vivo regulation of enhancer activity by introducing the 636, 643, and 840 enhancer-CreER T2 -GFP alleles into mice harboring a Pax6 null allele (Sey). We generated E11.5 embryos and found that Pax6 À/À mutants had reduced GFP expression from enhancers 636 and 840 in pallium ( Figures  7D, 7D 0 , 7F, and 7F 0 ). On the other hand, enhancer 643 continued to express GFP in the Pax6 À/À mutant, although the ventral boundary was less sharp ( Figure S5 ).
DISCUSSION
We generated stable transgenic mouse lines that express CreER T2 and GFP from 14 different enhancer elements with activity in distinct domains within the E11.5 pallium. These enhancer-CreER T2 -GFP lines have obvious broad utility for experimental manipulation of gene expression in specific domains and at specific times, including Cre-mediated gene deletion. Herein, using these unique tools, we (1) determined comprehensive regional fate map of the mouse pallium, which includes evidence for a set of progenitor domains defined by the activity of the enhancers ( Figure 1E ), and (2) began to decipher transcriptional mechanisms that control the enhancers using informatics, in vivo occupancy by TFs that regulate cortical patterning (PAX6, COUPTFI, and PBX1), and analysis of enhancer activity in Pax6 mutants. Below we elaborate on these discoveries and their implications for understanding cortical development, evolution, and disorders.
Dynamic Temporal Activity of Cortical Enhancers
Previously published transient transgenic analysis of cortical enhancers (Visel et al., 2013) interrogated only one developmental time point, E11.5. Using the stable enhancer lines described in this paper, we analyzed enhancer activity at different developmental ages. The majority of the enhancers maintained similar patterns of activity between E11.5 and E13.5; however, by E14.5, the activity of most of the enhancers decreased and/or became restricted to a smaller domain (Figure S2 ; Table S2 ). Thus, the set of enhancers we studied were 
Neuron
Enhancers Active in Cortical Protodomains primarily active during stages when regional patterning of pallium takes place ($E9.5-E12.5) and at early stages of neurogenesis ($E11-E13.5), suggesting that other enhancers have roles at later stages to drive gene expression for later developmental processes. Recently, Nord et al. (2013) provided evidence for distinct cohorts of enhancers that are active at different stages of brain development. In addition, some enhancers can be active at different stages. For example 660 expression, as its E11.5-E13.5 activity in the caudoventral cortex wanes, begins at $E13.5 in the neocortical subventricular zone ( Figure S2 ). The DlxI12b enhancer is active both in subpallial subventricular zone progenitor cells and in maturing and mature GABA neurons (Ghanem et al., 2007; Vogt et al., 2014) .
Fate-Mapping Analyses Define the Regional Derivatives from Distinct Pallial Progenitor Domains
The transient transgenic analysis of enhancer E11.5 activity led us to hypothesize subdivisions of the pallial progenitors (Figure 1D) . The stable transgenic analysis of E11.5 enhancer activity (GFP expression), and CreER T2 fate analyses at E17.5 and P30, supported many aspects of our initial model ( Figure 1D ) and importantly enabled us to describe the regional fates of each proposed progenitor domain ( Figure 1E and Table S2 ). Among the important observations, we discovered E11.5 progenitor domains that produce distinct subdivisions of the frontral cortex, providing information about where these distinct regions originate (Figure 3 ). Previous fate mapping of pallial regions have used transplantation (chick-quail; Garcia-Lopez et al., 2009) and Cre recombination methods, in which a constitutive Cre was driven from a gene locus. Thus, unlike our study, the previous Cre fate mapping did not obtain temporal-specific data, since generally the alleles were active over long periods of pallial development. Emx1-Cre and Foxg1 fate mapping showed that expression from these loci covers most of the pallium (Gorski et al., 2002; Hé bert and McConnell, 2000) . Wnt3a-Cre fate mapping labeled the cortical hem and derived Cajal-Retzius cells (Yoshida et al., 2006) . Dbx1-Cre fate mapping showed that the ventral pallium is another source for Cajal Retzius cells and that it contributes glutamatergic neurons to specific nuclei in the amygdala and ventral cortical structures (Bielle et al., 2005; Hirata et al., 2009; Teissier et al., 2010; Waclaw et al., 2010) . Thus, while these studies provide important information about the fates of pallial regions that express Cre over the course development, they do not provide a comprehensive fate map from multiple pallial progenitor domains from temporally restricted Cre activity.
The fate maps obtained using the 14 enhancer lines illuminated unexpected facets of the E11.5 expression domains. There was a rostrocaudal discontinuity in the properties of dorsomedial progenitor domains (between coronal planes 4 and 5 of schema; Figure 1E) ; rostrally, next to the septocommissural region, the dorsomedial progenitors generate the motor, cingulate, and prefrontral cortex; caudally, next to the choroid plexus, the dorsomedial progenitors generate the hippocampal complex and fimbrial area (hem). Within the rostral domain, we observed other rostrocaudal discontinuities, such as the restriction of the pallial septum, IL, and PrL domains within coronal planes 2 and 3 ( Figure 3J ).
Topographic discontinuities in caudal progenitor domains include the restriction of the Ch and F to the regions illustrated in coronal planes 4-7, the joining of the caudoventral (caudal) and rostrodorsal hippocampal domains in coronal plane 8, and the end of the hippocampal domain in coronal plane 9. Remarkably, we identified enhancers only active in the rostrodorsal (218, 348, and 643) or caudoventral (653 and 660) hippocampal primordia at E11.5.
The relative sizes of some progenitor domains were disproportionate to the size of their derived regions at E17.5 and P30, such as the size of Ch/F compared to the rest of the hippocampal complex (see sections 5-7; Figures 1E and 6G) . Thus, there was not a 1:1 proportional matching of the sizes of E11.5 progenitor and mature domains, providing evidence that the timing and relative distribution of regional growth is not uniform.
We provided evidence that the hippocampal primordium begins to expand at E12.5, based on the likewise expanded activity of enhancer 643 ( Figure 6 ). Furthermore, the activity of enhancer 1,050 becomes progressively focused in the hippocampal region between E11.5 and E14.5 ( Figure S2K ). Thus, further investigations into the transcriptional process that drives hippocampal development will be aided by understanding the transcription mechanisms that drive enhancer 643 and enhancer 1,050 activities in the hippocampal primordium.
While the aim of our anatomical analyses was to derive a pallial fate map, we made some observations about regional histogenesis and cell-type generation. Tamoxifen induction of recombination at E10.5 generally resulted in radial clones of cells that spanned the cortical plate, providing evidence that this set of enhancers is not lineage restricted with regard to subsequent laminar fate. This adds evidence for the model that intrinsically produced neurons for each cortical layer are sequentially generated from the same neuroepithelial progenitor (Leone et al., 2008; Guo et al., 2013) , although it does not eliminate the possibility that enhancers will be discovered that show more restricted fate properties. Indeed, as has already been elucidated, excitatory neurons of layer 1 (Cajal Retzius cells) are generated from specific domains at the pallial perimeter (Bielle et al., 2005; Yoshida et al., 2006; Puelles, 2011) ; several of our enhancers (192, 348, and 643) provide additional evidence for this process ( Figures S2A, S2D , and S2F). Furthermore, because the enhancers drive CreER T2 , tamoxifen induction of Cre activity at later time points can be used to study later stages of neuroand gliogenesis with enhancer lines that maintain progenitor cell activity after E11.5 (Table S2 ).
Identification of Enhancers that Detect Pallial Subdivisions: Insights into the Transcription Networks Driving Pallial Regional Development and Evolution
In the cellular blastoderm of Drosophila, enhancer activities reveal developmental domains generated by the combinatorial activity of TFs that ultimately underlie body subdivisions, as exemplified by enhancers that drive gap-gene expression (Perry et al., 2011) . Enhancer activity domains can be smaller and sharper than the expression domains of the TFs that drive their expression (Perry et al., 2011) . In the pallial primordium CoupTFI, Dmrta2 (Dmrt5), Emx2, Lhx2, Pax6, Pbx1, and Sp8, TFs that control pallial regionalization, are expressed in broad gradients (Bishop et al., 2000; Galceran et al., 2000; Yun et al., 2001; Mallamaci and Stoykova, 2006; Armentano et al., 2007; Sahara et al., 2007; Faedo et al., 2008; Mangale et al., 2008; Chou et al., 2009; Konno et al., 2012; Borello et al., 2013; Saulnier et al., 2013) . Positional information appears to lie in these TF gradients, and in their combinatorial interactions.
Here, we provide evidence for a mechanism that can integrate this transcriptional information to generate discrete pallial subdivisions. Many of the enhancers show patterns of activity at E11.5 that are more discrete than the broadly expressed patterns of aforementioned patterning TFs. Thus, we suggest these enhancer activities reflect the integration of transcriptional activities that together pattern the pallium. Furthermore, it is possible that these and related enhancers are fundamental elements that have driven pallial evolution, as duplication and transposition of these distant-acting regulators have the potential to alter gene expression. Significantly, our gain-of-function transgenic assays show the ability of these enhancers to function in a variety of chromosomal locations.
Currently, we do not have definitive evidence for the gene(s) that each of these enhancers regulates. However, based on proximity, and similar expression profiles, we have some predictions for enhancer/gene pairs ( Figure S2 and Table S2 ). For instance, the activity of enhancers 1,006, 1,050, and 1,172, which have genomic positions close to Wnt8b, Lef1, and CoupTFI, respectively, closely resembles the pallial expression of these genes ( Figures S2J, S2K , and S2M; Visel et al., 2013) . Future studies are required to test for enhancer/gene interactions using chromatin conformation methods (Clowney et al., 2012) , as well as loss-of-function mutagenesis. While some enhancers are clearly required for gene expression (Shim et al., 2012) , there is evidence that enhancer redundancy exists (Ahituv et al., 2007; Lagha et al., 2012) .
Mechanisms that Regulate Enhancer Activity
We used informatic, biochemical, and genetic approaches to begin deciphering transcriptional mechanisms that control the activity of the enhancers. Informatic methods provide insights into candidate TFs that may regulate enhancer activities (Shim et al., 2012; Visel et al., 2013) . We used a machine learning method to identify nucleotide signatures that may underlie regional differences in enhancer activities. Transcriptional binding sites that were enriched in enhancers with and without MP activity led us to identify TFs with expression either in, or excluded from, the Ch/F part of the E11.5 MP (Figures S3 and  S4 ). This is interesting because histogenesis of the primordium of the choroid plexus (Ch) is distinct from the rest of the pallium, as the Ch is a nonneural tissue generated from the neural tube roof plate (Puelles, 2014) , and the fimbrial area (cortical hem) represents the border between roof and alar plate tissues. As more pallial enhancers are defined, and as the binding sites for additional TFs are identified, it is likely that informatic approaches will gain power in defining sequences that control regional expression.
Next, we used ChIP-seq to test whether the enhancers under study were bound in vivo in the E12.5 mouse cortex by PAX6, COUPTFI, and PBX1, three transcription factors that regulate pallial patterning (Bishop et al., 2000; Yun et al., 2001; Mallamaci and Stoykova, 2006; Armentano et al., 2007; Sahara et al., 2007; Faedo et al., 2008; Borello et al., 2013; O.G. and J.L.R.R., unpublished data) . Previous analyses of PAX6 binding in the developing pallium used ChIP-promoterChIP and thus did not examine PAX6 binding to the enhancers described herein (Sansom et al., 2009; Xie et al., 2013) . Our ChIP-seq analyses showed that PAX6 (a general marker for the telencephalic pallium; Puelles et al., 2000) bound to all of the enhancers globally expressed in the pallium ( Figure 7A and Table S8 ), suggesting that PAX6 may have a fundamental role coordinating pallial properties.
Enhancers with more restricted intrapallial regional activity had reduced frequencies of PAX6 binding, particularly when LVP activity was absent ( Figure 7A and Table S8 ). In addition, COUPTFI and PBX1 bound few MP enhancers ( Figure 7A and Table S8 ). Both Pax6 and CoupTFI regulate dorsoventral patterning of the pallium; and they both promote ventral identity (Yun et al., 2001; Faedo et al., 2008) . Consequently, our ChIP-seq analysis provides evidence that these two TFs may regulate dorsoventral pallial patterning by promoting activity of enhancers specifically active in the VP, LP, and DP.
This concept is consistent with that the fact that PAX6 has a potent role in patterning the ventrolateral cortex ( Figure 7A ; Yun et al., 2001) . Furthermore, transcription assays in tissue culture showed that PAX6 strongly activated ($15-fold) 636, the enhancer with VP and LP activity ( Figure 7B ). On the other hand, PAX6-mediated activation was lower for enhancers with MP activity (840 and 643), suggesting that they have elements that antagonize activation by PAX6.
To test hypotheses generated by the ChIP-seq and transfection assays, we examined 636 and 840 enhancer activities in Pax6 loss-of-function mutants. As predicted by their PAX6 ChIP-seq peaks and their activation by PAX6 in the cell culture transcription assay, 636 and 840 pallial activity was greatly reduced in E11.5 Pax6 À/À ( Figures 7D, 7D 0 , 7F, and 7F 0 ).
Implications
The identification of human enhancers with restricted spatial and temporal activities in pallial protodomains demonstrates that the genome has relatively small (0.5-3 kb) regulatory elements that can integrate transcriptional information to generate highly specific patterns of gene expression, even in ectopic genomic loci (herein and Visel et al., 2013) . Importantly, the enhancer activity patterns for the most part do not resemble the expression of single known TFs, highlighting the enhancers' roles as spatial integrators of regulatory information. This knowledge opens the door to deciphering the sequence-specific regulation of enhancer activity and how mutations alter their function and contribute to disease.
EXPERIMENTAL PROCEDURES
Generation and Characterization of Stable Enhancer Transgenic Mice PCR-amplified human enhancer regions were subcloned into Hsp68-CreERT2-IRES-GFP (Visel et al., 2013) and used to generate stable transgenic mice. Founders were screened using CreERT2 specific primers. Enhancer transgenic embryos were examined for GFP expression. For fate mapping, enhancer lines were crossed to Ai14 Cre-reporter mice (Madisen et al., 2010) . Tamoxifen was administered at E9.5 or E10.5; tdtomato was assayed at later stages. Stable transgenic mice were crossed to the Pax6 mutant. Mice were used in accordance with National Institutes of Health and UCSF guidelines.
Histology
Immunohistochemistry was performed as in Flandin et al. (2010) . RNA in situ hybridization and in situ/immunohistochemistry was performed as in Jeong et al. (2008) .
Identification of Region Specific Motifs
See Supplemental Experimental Procedures for details.
Chromatin Immunoprecipitation
ChIP was performed using E12.5 or E13.5 cortex and Pax6 (Millipore), CoupTf1 (R&D systems), and Pbx1/2/3 (C-20, Santa Cruz Biotechnology) antibodies (McKenna et al., 2011) . Libraries were prepared using an Ovation Ultralow DR Multiplex System (Nugen). Reads from ChIP, input, and negative control (IgG) libraries were mapped to the mouse genome (mm9) using BWA and peaks were called using MACS considering both input and IgG as the control sample with filtering to remove peaks in repeat regions.
Luciferase Assay
Enhancer activity was studied in P19 cells (Farah et al., 2000) cotransfected with pCAGGs (empty) or pCAGGs-Pax6/CoupTf1/Pbx1, and Promega pGL4.23 luciferase reporter (empty) or containing an enhancer element upstream of the luciferase gene (pGL4.23-enhancer).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures, fives figures, and eight tables and can be found with this article online at http://dx.doi.org/10.1016/j.neuron.2014.04.014.
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